An Open-label, Randomised, Four-period, Four-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioavailability of Ticagrelor Orodispersible Tablets, Compared to Ticagrelor Immediate-release Tablets in Healthy Subjects

Trial Profile

An Open-label, Randomised, Four-period, Four-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioavailability of Ticagrelor Orodispersible Tablets, Compared to Ticagrelor Immediate-release Tablets in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Abdominal aortic aneurysm; Acute coronary syndromes; Cardiovascular disorders; Community-acquired pneumonia; Coronary artery disease; Peripheral arterial disorders; Sickle cell anaemia; Stroke
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 16 Jun 2015 Planned End Date changed from 1 Aug 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top